GATOR1复杂控制着西斯的敏感性
Zhenrui Pan1,2, Hanxiao Zhang1, Xia Xiao1
1CNRS UMR9018, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
Cell death & disease
|December 30, 2025
概括
GATOR1复合体,不仅仅是NPRL2,对于癌症中对西斯普拉丁的耐药性至关重要. 删除GATOR1组件会增加耐药性,而过度表达会恢复敏感性,为化疗耐药性提供新的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 西斯是一种用于上皮癌的关键化疗,但耐药性是主要障碍.
- 低NPRL2表达以前与西斯普拉丁耐药性有关.
- NPRL2,NPRL3和DEPDC5形成了GATOR1复合体,调节mTORC1,这种复合体在耐西斯类癌症中经常失调.
研究的目的:
- 调查GATOR1复合体在NPRL2.2之外的西斯普拉丁耐药性中的作用.
- 为了比较内在和获得的西斯普拉丁耐药性模型.
- 为了确定基底的分子机制 GATOR1介导的西斯抗性.
主要方法:
- 使用了具有GATOR1删除的BEAS-2B细胞作为内在电阻模型.
- 采用耐思的非小细胞肺癌细胞系 (A549,H460,H1975) 来获得耐药性.
- 分析了输送体表达 (ATP7A,CTR2,LRRC8A),DNA损伤反应,mTORC1活动,并进行了转录基因分析.
主要成果:
- 删除任何 GATOR1 组件会导致对西斯普拉丁的耐药性;过度表达会恢复敏感性.
- 删除GATOR1可以调节 cisplatin 流量 (ATP7A) 的上升,并调节流量 (CTR2,LRRC8A) 的下降.
- 具有GATOR1缺失的细胞显示DNA损伤反应和mTORC1活性增加,阻碍了西斯-DNA adduct 的形成.
结论:
- GATOR1复合体,不仅仅是NPRL2,在内在和获得的西斯普拉丁耐药性中发挥着重要作用.
- 改变GATOR1成分表达或抑制mTORC1可以调节西斯的敏感性.
- 由于GATOR1在抗化学物质方面的新功能,因此需要考虑开发新的治疗策略来对抗西斯普拉丁耐药性.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:23Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K